Product Description
Our lead drug candidate, CZ48, is an improved form of the drug 9-NitroCamptothecin (9NC)Ê. CZ48 has been designed to significantly improve blood levels compared to 9NC,, yet retain this high degree of anti-cancer activity. In vitro studies show that when CZ48 is incubated with Human Serum Albumin (HSA), blood levels of active drug are increased more than tenfold compared to 9NC. This increase in drug availability should translate into an even higher degree of efficacy. (Sourced from: http://www.caopharmaceuticals.com/lead-drug.html)
Mechanisms of Action: SARM Activator,CD38 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cao
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CZ48 | P1 |
Unknown status |
Lymphoma |
2019-10-01 |
41% |
INST CZ48-01 | P1 |
Completed |
Lymphoma |
2012-12-01 |